The global cold plasma market size 2026 was valued at USD 161.7 million in 2025 and is projected to grow from USD 182.8 million in 2026 to USD 498.0 million by 2034, at a CAGR of 13.3% during the forecast period. Europe led the market with a 36.92% share in 2025.
Cold plasma systems inactivate pathogens, modify biological microenvironments, and sterilize surfaces — all without using heat, preserving tissue and material integrity. This makes them well-suited for chronic wound management, dermatology, infection control, and clinical surface disinfection.
Key Market Drivers
Infection Prevention & Better Patient Outcomes are the primary growth catalysts. Hospitals and clinics are increasingly prioritizing infection control and safer treatment options. Cold plasma devices are gaining recognition for their ability to reduce contamination risk in wound-care and dermatology settings. A study by German biotech Viromed Medical (May 2025) found its cold plasma system achieved 100% infection prevention against methicillin-resistant Staphylococcus aureus (MRSA).
Additional drivers include rising emphasis on antibiotic-free care, faster healing outcomes, and reduced hospital re-admissions.
Get a Free Sample PDF - https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/cold-plasma-market-114745
Market Restraints & Challenges
Lack of standardization remains a key hurdle. Cold Atmospheric Plasma (CAP) systems vary widely in energy source, gas composition, and exposure duration, making uniform clinical protocols difficult to establish. Hospitals demand reproducible outcomes before integrating CAP into treatment workflows.
Reimbursement variability and operational integration complexity also moderate adoption. Cold plasma often requires repeated sessions, and without standardized clinical pathways, treatment plans differ significantly between practitioners, slowing institutional uptake.
Market Opportunities & Trends
Home-based cold plasma devices represent a significant growth opportunity. Many patients with chronic wounds or skin conditions need frequent care; home-use devices allow treatment without repeated clinic visits. In June 2025, hyped science GmbH launched PHLAS, a next-generation cold plasma skincare device designed specifically for homecare settings.
A notable market trend is the shift toward portable, clinic-friendly devices. Compact, ergonomic systems support frequent treatment sessions and easy integration into standard wound-care pathways. In May 2024, US Medical Innovations received FDA approval for its Canady Helios Cold Plasma ablation system, highlighting momentum in portable device approvals.
Segmentation Highlights
By Product Type: Cold plasma systems led the market in 2025, as healthcare providers prefer complete platforms for integration into care workflows. The accessories segment is growing fastest at a CAGR of 15.8%.
By Technology: The atmospheric pressure plasma jet segment dominates with a projected 60.6% share in 2026, favored for its ease of bedside operation without complex preparation. The dielectric barrier discharge segment is growing at a CAGR of 12.1%.
By Application: Wound healing commands the largest share — an estimated 57.2% in 2026. Conditions such as diabetic foot ulcers, pressure sores, and venous leg ulcers require prolonged, repeated care, making cold plasma a complementary fit. The cancer application segment is the fastest growing at a CAGR of 13.5%.
By End-User: Hospitals & specialty clinics lead, given their dedicated staff, treatment infrastructure, and procurement capacity. Academic & research institutes are projected to grow at a CAGR of 13.8%.
Competitive Landscape
The market is moderately consolidated, led by specialized European players with a growing U.S. entrant base. Key companies include:
- terraplasma medical GmbH (Germany)
- ADTEC Plasma Technology Co., Ltd. (Japan)
- Relyon Plasma GmbH (Germany)
- Neoplas Tools GmbH (Germany)
- Apyx Medical Corporation (U.S.)
- Plasmacure B.V., CINOGY, and US Medical Innovations
Notable recent developments include Plasmacure raising USD 6.9 million (July 2025) for global expansion, and Adtec Healthcare receiving USD 12.0 million in funding (July 2025) to expand its U.S. cold plasma technology footprint.